Collectionner le produit
Détails du produit
Synonyms
BTLA, CD272
Source
Human BTLA, Fc Tag (BTA-H5255) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Thr 134 (Accession # NP_001078826.1).
Predicted N-terminus: Lys 31
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 38.7 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human BTLA, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA
Immobilized Human HVEM, His Tag (Cat. No. HVM-H52E9) at 5 μg/mL (100 μL/well) can bind Human BTLA, Fc Tag (Cat. No. BTA-H5255) with a linear range of 0.04-1.25 μg/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
FAQ
- Product
Why are different expression ranges (31–134 and 31–150) used for human BTLA proteins?
The different lengths of human BTLA proteins correspond to different isoforms. The aa31–134 sequence represents isoform 2, while aa31–150 corresponds to isoform 1. ACRO provides BTLA proteins of varying lengths to meet diverse customer requirements.
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
B- and T-lymphocyte attenuator
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
6 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
